Home > Press > Hana Biosciences to Present Data On Marqibo, Its Lead Novel Anti-Cancer Compound, At 2008 American Society of Hematology (ASH) Meeting
Abstract:
Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that several presentations related to the Company's lead anti-cancer compound, Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)), will be presented at the upcoming annual meeting of the American Society of Hematology (ASH) in San Francisco during December 6-9, 2008.
Hana Biosciences to Present Data On Marqibo, Its Lead Novel Anti-Cancer Compound, At 2008 American Society of Hematology (ASH) Meeting
SOUTH SAN FRANCISCO, CA | Posted on December 1st, 2008
The following posters will be presented in Hall A of the Moscone Center at the ASH annual meeting. Text of these abstracts can be viewed on the ASH website at www.hematology.org.
* In Vivo Anti-Tumor Efficacy of Vincristine Sulfate Liposomes
Injection (VSLI, Marqibo) in Multiple Myeloma (abstract #2760;
Sunday, Dec. 7, 6:00 PM)
* Peripheral Neuropathy Profile of Vincristine Sulfate Liposomes
Injection (VSLI, Marqibo), a Nanoparticle Vincristine Formulation,
in Adult Subjects with Relapsed/Refractory Acute Lymphoblastic
Leukemia (ALL) and Non-Hodgkin's Lymphoma (NHL) (abstract #2928;
Monday, Dec. 8, 5:30 PM)
* Phase 1 Study of Weekly Vincristine Sulfate (VCR) Liposomes
Injection (VSLI, Marqibo) Plus Dexamethasone in Adults with Relapsed
or Refractory Acute Lymphoblastic Leukemia (ALL) (abstract #2930;
Monday, Dec. 8, 5:30 PM)
####
About Hana Biosciences
Hana Biosciences, Inc. (Nasdaq:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of cancer care. The company is committed to creating value by building a best-in-class team, accelerating the development of lead product candidates, expanding its pipeline by being an alliance partner of choice, and nurturing a unique company culture.
For more information, please click here
Contacts:
Hana Biosciences
Investor & Media Contacts:
Investor Relations Team
(650) 588-6641
Invigorate Communications
Gregory Gin
(908) 376-7737
Copyright © GlobeNewswire, Inc.
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
News and information
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
Beautiful "flowers" self-assemble in a beaker: Elaborate nanostructures blossom from a chemical reaction perfected at Harvard May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013
Nanomedicine
Nanotechnology could help fight diabetes: Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed May 16th, 2013
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Pitt Chemists Demonstrate Nanoscale Alloys So Bright They Could Have Potential Medical Applications: “Think about a particle that will not only help researchers detect cancer sooner but be used to treat the tumor, too.” May 15th, 2013
Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells May 15th, 2013
Announcements
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
NIA Public Briefing: Nanotechnology and the Council of Europe May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013
Events/Classes
Interactive Printed Products – New Applications Enabled by Organic and Printed Electronics May 16th, 2013
Nanometrics Announces Upcoming Investor Events May 14th, 2013
INSCX™ exchange to present a nanotechnology-based Emission Reduction Programme, Ankara, Turkey, June 2013 May 14th, 2013
VDMA: New “Photonics Industry Report 2013” presented May 14th, 2013